Hepion Pharmaceuticals, Inc. (HEPA)
| Market Cap | 13.75M +1,720.5% |
| Revenue (ttm) | n/a |
| Net Income | -3.19M |
| EPS | -0.25 |
| Shares Out | 98.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,503 |
| Open | 0.1350 |
| Previous Close | 0.1500 |
| Day's Range | 0.1350 - 0.2200 |
| 52-Week Range | 0.0341 - 0.2200 |
| Beta | 1.75 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and ... [Read more]
Financial Performance
Financial StatementsNews
Hepion Pharmaceuticals receives FDA feedback for GV104
Hepion Pharmaceuticals (HEPA) reported results from an expanded modeling and simulation analysis of GV104, conducted by its wholly-owned subsidiary Gravitas Life Sciences, and the written feedback rec...
Hepion Pharmaceuticals receives positive FDA response on GV104
Hepion Pharmaceuticals (HEPA) announced that its wholly-owned subsidiary Gravitas Life Sciences has received written responses from the U.S. Food and Drug Administration to its Type B pre-Investigatio...
Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
- FDA's Division of Psychiatry issued written responses to a Type B pre-IND meeting request covering the regulatory pathway, the nonclinical package, and the design of a planned Phase 2 study- - Confi...
Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
- Acquisition adds GV104, a clinical-stage opioid countermeasure with a 505(b)(2) pathway and an active investigational new drug application, and GV023, an oral formulation of an approved anti-TNF ant...
Hepion Pharmaceuticals Quarterly report: Q2 2026
Hepion Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 13, 2026.
Hepion Pharmaceuticals Quarterly report: Q1 2026
Hepion Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 14, 2026.
Hepion Pharmaceuticals Proxy statement: Proxy filing
Hepion Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Hepion Pharmaceuticals Proxy statement: Proxy filing
Hepion Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Hepion Pharmaceuticals (HEPA), 159.2% surge in interest S...
Hepion Pharmaceuticals Annual report: Q4 2025
Hepion Pharmaceuticals has published its Q4 2025 annual report on March 12, 2026.
Hepion Pharmaceuticals in-licenses ctRNA biomarker assay from Cirna Diagnostics
Hepion Pharmaceuticals (HEPA) has in-licensed from Cirna Diagnostics, a novel biomarker assay that detects mutant circulating tumor RNA to facilitate early diagnosis of hepatocellular carcinoma in hig...
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion's strategic shift to advancing clinically proven li...
Hepion Pharmaceuticals Quarterly report: Q3 2025
Hepion Pharmaceuticals has published its Q3 2025 quarterly earnings report on November 12, 2025.
Hepion Pharmaceuticals Quarterly report: Q2 2025
Hepion Pharmaceuticals has published its Q2 2025 quarterly earnings report on August 14, 2025.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: iBio (IBIO), 681% surge in interest Hepion Pharmaceutical...
Hepion Pharmaceuticals completes application to OTCQB
Hepion Pharmaceuticals (HEPA) has completed the process of transitioning to the OTCQB Venture Market. The Company’s common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with…
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for ce...
Hepion Pharmaceuticals appoints Kaouthar Lbiati as interim CEO
Hepion Pharmaceuticals (HEPA) announced that Kaouthar Lbiati has been named as interim CEO, effective June 16, 2025. Dr. Lbiati is replacing John Brancaccio, who is retiring for personal reasons. Lbia...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Hepion Pharmaceuticals (HEPA), 102% surge in interest Pip...
Hepion announces receipt of delisting notification from Nasdaq
Hepion Pharmaceuticals (HEPA) announced that on May 9, the company received written notice from the Office of General Counsel of The Nasdaq Stock Market indicating that the Nasdaq Hearings Panel…
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatoh...
Hepion Pharmaceuticals enters binding LOI with New Day Diagnostics
Hepion Pharmaceuticals (HEPA) announced that it has entered into a binding letter of intent, LOI, with New Day Diagnostics LLC to in-license diagnostic tests for celiac disease, respiratory multiplex,...
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatoh...
Hepion Pharmaceuticals Proxy statement: Proxy Filing
Hepion Pharmaceuticals filed a proxy statement on April 28, 2025, providing details for shareholder voting and corporate governance matters.
Hepion Pharmaceuticals Proxy statement: Proxy Filing
Hepion Pharmaceuticals filed a proxy statement on April 23, 2025, providing details for shareholder voting and corporate governance matters.